Thursday, April 11, 2019 Daily Archives

World’s first Soliris biosimilar launched in Russia

by

Russian biopharma Generium has launched Elizaria, a biosimilar version of Alexion’s Soliris (eculizumab) developed using the SUREtechnology Platform from Selexis. Approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), Soliris (eculizumab) pulled in $3.6 billion (€3.2 billion) in global sales for Alexion Pharmaceuticals in 2018. While Alexion is confident its IP will restrict direct competition in the US and Europe potentially up until 2027, the first biosimilar has been approved and launched in Russia in…

April 11, 2019

ekko™: How Acoustics Cell Processing is Changing Cell and Gene Manufacturing

by

This presentation features: Kevin Lannon, Director of Global Sales, FloDesign Sonics With an ever-increasing number of cell and gene therapies approaching commercialization, the industry is looking for scalable manufacturing solutions. In order to truly see a step change in improvement, it is crucial for tool providers to design equipment specifically for the GMP environment and the unique needs of cell and gene processing. This presentation will outline: How acoustophoresis and the ekko™ platform is changing the cell processing paradigm Overview…

April 11, 2019

Encroaching titer, hidden danger: Upstream intensification and the downstream mess

by

Increased titers are driving the need to move to semi and fully-continuous processing in the downstream, UCB’s Stefanos Grammatikos told BPI Europe delegates. In efforts to intensify bioprocesses and accelerate development, industry has traditionally looked to increasing titers. Since the early days of biomanufacturing thirty years ago, titers have risen from less than 0.5 g/L to mid-to-high single-digits. However, some firms claim they are able to drive titers far higher, either through the use of non-mammalian expression systems (in the…

April 11, 2019